

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS
and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002

NEWS HOURS STN Operating Hours/Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:11:31 ON 27 MAY 2002

09/905,644

V. Balasubramanian

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:11:40 ON 27 MAY 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 24 MAY 2002 HIGHEST RN 421765-63-1

DICTIONARY FILE UPDATES: 24 MAY 2002 HIGHEST RN 421765-63-1

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09905644.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 C,O,S

G3 O,S,N,P,[@1]

09/905,644

Structure attributes must be viewed using STN Express query preparation.

SAMPLE SCREEN SEARCH COMPLETED - 773 TO ITERATE

10 ANSWERS

BATCH ** COMPLETE **


PROJECTED ANSWERS: 11 TO 389

=> d scan

IN 1(2H)-Pyridineacetamide, 6-(1,1-dimethylethyl)-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI)

MF C31 H35 N3 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

IN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI)

MF C27 H27 N3 O6


Absolute stereochemistry.

V. Balasubramanian



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(3-pyridinylsulfonyl)amino]- (9CI)
 MF C18 H23 N7 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1(2H)-Pyridineacetamide, 3-[[[4-(acetamino)phenyl]sulfonyl]amino]-N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo- (9CI)
 MF C21 H27 N7 O6 S

V. Balasubramanian




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(phenylsulfonyl)amino]- (9CI)
MF C19 H24 N6 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(2,3-dichlorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI)
MF C20 H24 Cl2 N6 O5 S



V. Balasubramanian

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(3-fluorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI)
MF C20 H25 F N6 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-4-(2-cyclohexylethyl)-3-[(methylsulfonyl)amino]-2-oxo-, mono(trifluoroacetate) (salt) (9CI)
MF C22 H36 N6 O5 S . C2 H F3 O2


CM 1

Absolute stereochemistry.




CM 2

V. Balasubramanian




L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-6-methyl-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI)
MF C23 H32 N6 O5 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI)
MF C27 H27 N3 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

V. Balasubramanian

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 13:12:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 15959 TO ITERATE

100.0% PROCESSED 15959 ITERATIONS 143 ANSWERS
SEARCH TIME: 00.00.04

L3 143 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 140.66 140.87

FILE 'CAPLUS' ENTERED AT 13:12:40 ON 27 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2002 VOL 136 ISS 22
FILE LAST UPDATED: 24 May 2002 (20020524/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L4 14 L3

=> d l4 1-14 bib hitstr

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 2002:84598 CAPLUS
DN 136:102658
TI Preparation of aromatic heterocyclic derivatives as enzyme inhibitors
IN Brunck, Terence Kevin; Tamura, Susan Y.; Semple, Joseph Edward; Ardecky, Robert John; Ge, Yu; Ripka, William Charles
PA Corvas International, Inc., USA
SO U.S., 84 pp., Cont.-in-part of U.S. 6,011,158.
CODEN: USXXAM


09/905,644

V. Balasubramanian

DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6342504	B1	20020129	US 1999-194855	19991221
	US 5656645	A	19970812	US 1995-484506	19950607
	US 5658930	A	19970819	US 1995-481660	19950607
	WO 9618644	A1	19960620	WO 1995-US16410	19951213
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6008351	A	19991228	US 1995-573775	19951218
	US 6011158	A	20000104	US 1996-659983	19960607
	WO 9746207	A2	19971211	WO 1997-US9818	19970609
	WO 9746207	A3	19980423		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1994-356833	A2	19941213		
	US 1995-481660	A2	19950607		
	US 1995-484506	A2	19950607		
	WO 1995-US16410	A2	19951213		
	US 1995-573775	A2	19951218		
	US 1996-659983	A2	19960607		
	WO 1997-US9818	W	19970609		
OS	MARPAT 136:102658				
IT	199873-32-0P 199873-70-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of arom. heterocyclic derivs. as enzyme inhibitors)				
RN	199873-32-0 CAPLUS				
CN	1(2H)-Pyridineacetamide, N-[(2S,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 199873-70-6 CAPLUS

09/905,644

V. Balasubramanian

CN 1(2H)-Pyridineacetamide, N-[(2R,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 193278-20-5P 195204-07-0P 199873-27-3P
252860-83-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. heterocyclic derivs. as enzyme inhibitors)

RN 193278-20-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-3-[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195204-07-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-oxo-3-[(phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 195204-06-9

CMF C22 H30 N6 O5 S

Absolute stereochemistry.




CRN 64-19-7
CMF C2 H4 O2



RN 199873-27-3 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidiny]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252860-83-6 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-3-
[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo-, (3S)-, monoacetate (9CI)
(CA INDEX NAME)

CM 1


CRN 199873-29-5
CMF C22 H29 F N6 O5 S

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 2000:861677 CAPLUS
DN 134:29437
TI Novel oxazaheterocycles as protease inhibitors
IN Wang, Aihua; Lu, Tianbao; Tomczuk, Bruce E.; Soll, Richard M.; Spurlino, John; Bone, Roger
PA 3-Dimensional Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073302	A1	20001207	WO 2000-US14553	20000526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 6326492 B1 20011204 US 2000-578487 20000526 EP 1189901 A1 20020327 EP 2000-932792 20000526 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO PRAI US 1999-136386P P 19990527 WO 2000-US14553 W 20000526 IT 311811-25-3P 311811-26-4P 311811-27-5P 311811-28-6P 311811-29-7P 311811-30-0P 311811-31-1P 311811-32-2P 311811-33-3P 311811-34-4P 311811-35-5P 311811-36-6P 311811-37-7P 311811-38-8P 311811-39-9P 311811-40-2P 311811-41-3P 311811-42-4P 311811-43-5P 311811-44-6P 311811-45-7P 311811-46-8P 311811-47-9P 311811-48-0P 311811-49-1P 311811-50-4P 311811-51-5P 311811-52-6P 311811-53-7P 311811-54-8P 311811-55-9P 311811-56-0P 311811-57-1P 311811-58-2P 311811-59-3P 311811-60-6P 311811-61-7P 311811-62-8P 311811-63-9P 311811-64-0P 311811-65-1P 311811-66-2P 311811-67-3P 311811-69-5P 311811-71-9P 311811-74-2P 311811-75-3P 311811-76-4P 311811-77-5P 311811-78-6P 311811-79-7P 311811-80-0P 311811-81-1P 311811-82-2P 311811-83-3P 311811-84-4P				

V. Balasubramanian

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and biol. activity of oxazaheterocycles as protease inhibitors)

RN 311811-25-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 311811-26-4 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 311811-25-3


CMF C20 H26 N6 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 311811-27-5 CAPLUS

09/905,644


V. Balasubramanian

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 311811-28-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 311811-29-7 CAPLUS


CN Carbamic acid, [1-[2-[[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]amino]-2-oxoethyl]-1,2-dihydro-6-methyl-2-oxo-3-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 311811-30-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(3-chlorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-31-1 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 311811-32-2 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[2-iodophenyl]methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-33-3 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[2-chlorophenyl]methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-34-4 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(2-bromophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-35-5 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(3-fluorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-36-6 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(4-chlorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-37-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(2-chloro-6-fluorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-38-8 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-39-9 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(2,3-dichlorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-40-2 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(3,4-difluorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI)
(CA INDEX NAME)



RN 311811-41-3 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(2,4-dichlorophenyl)methyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI)
(CA INDEX NAME)



RN 311811-42-4 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[(3-chlorophenyl)sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-43-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[3-bromophenylsulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-44-6 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[3-fluorophenylsulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-45-7 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[1-naphthalenylsulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-46-8 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[(2-naphthalenylsulfonyl)amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-47-9 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[2-(chlorophenyl)sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-48-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[4-(chlorophenyl)sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-49-1 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 311811-50-4 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[1-naphthalenylmethyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-51-5 CAPLUS


V. Balasubramanian

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[(2-naphthalenylmethyl) sulfonyl] amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 311811-52-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(4-bromophenyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-53-7 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(4-fluorophenyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-54-8 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(4-iodophenyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-55-9 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[4-methoxyphenyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-56-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 311811-57-1 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-58-2 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(3,4-dimethoxyphenyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-59-3 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(2-thienylsulfonyl) amino]- (9CI) (CA INDEX NAME)



RN 311811-60-6 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(4-ethenylphenyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-61-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[2-butoxy-5-(1,1-dimethylpropyl)phenyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-62-8 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[[3-nitrophenyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-63-9 CAPLUS


CN 1(2H)-Pyridineacetamide, 3-[[[4-(acetamido)phenyl]sulfonyl]amino]-N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-64-0 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI)
(CA INDEX NAME)



RN 311811-65-1 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[4-(tert-butyl)phenyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-66-2 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[[4-(methylsulfonyl)phenyl]sulfonyl]amino]-2-oxo- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 311811-67-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-69-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 311811-71-9 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


V. Balasubramanian

yl]-3-[[(2-methoxy-5-methylphenyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI)
(CA INDEX NAME)




RN 311811-74-2 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(1,1'-biphenyl)-4-ylsulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-75-3 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(5-chloro-2-thienyl) sulfonyl] amino]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-76-4 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(8-quinolinylsulfonyl) amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 311811-77-5 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(5-quinolinylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 311811-78-6 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[[1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-2-oxo- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 311811-79-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-3-[(3-methyl-8-quinoliny) sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-80-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(2-pyridinylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 311811-81-1 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-methyl-2-oxo-3-[(3-pyridinylsulfonyl)amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 311811-82-2 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo- (9CI)
(CA INDEX NAME)




RN 311811-83-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-6-ethyl-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 311811-84-4 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-(aminoiminomethyl)tetrahydro-2H-1,2-oxazin-5-yl]-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-6-propyl- (9CI) (CA INDEX NAME)




IT 311812-63-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and biol. activity of oxazaheterocycles as protease inhibitors)

RN 311812-63-2 CAPLUS

CN Carbamic acid, [imino[tetrahydro-5-[[[6-methyl-3-[(3-methylphenyl)sulfonyl]amino]-2-oxo-1(2H)-pyridinyl]acetyl]amino]-2H-1,2-oxazin-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 2000:591006 CAPLUS

DN 133:328956

TI Determination of enantiomers in a synthetic argininal peptide using capillary zone electrophoresis and high-performance liquid chromatography

AU Dan, N.; Ganesan, R.; Flood, K. G.; Tsai, D.; Reif, V. D.

CS Department of Chemical Development, Department of Analytical Development, Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA

SO Journal of Chromatography, A (2000), 891(1), 115-127

CODEN: JCRAEY; ISSN: 0021-9673

PB Elsevier Science B.V.

DT Journal

LA English

IT 303114-41-2 303114-42-3 303114-43-4

303114-44-5

RL: ANT (Analyte); PEP (Physical, engineering or chemical process); ANST (Analytical study); PROC (Process)

(detr. of enantiomers in a synthetic argininal peptide using capillary zone electrophoresis and high-performance liq. chromatog.)


RN 303114-41-2 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2S,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[3-methoxyphenyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian

NAME)


Absolute stereochemistry.



RN 303114-42-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2R,3R)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[3-methoxyphenyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 303114-43-4 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2R,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[3-methoxyphenyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 303114-44-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2S,3R)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[3-methoxyphenyl)sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 2000:10664 CAPLUS
DN 132:64536
TI Preparation of aromatic heterocyclic derivatives as enzyme inhibitors
IN Tamura, Susan Yoshiko; Semple, Joseph Edward; Ripka, William Charles;
Ardecky, Robert John; Ge, Yu; Carpenter, Stephen H.; Brunck, Terence K.;
Lim-Wilby, Marguerita S. L.; Nutt, Ruth F.; Abelman, Matthew M.
PA Corvas International, Inc., USA
SO U.S., 86 pp., Cont.-in-part of U.S. Ser. No. 573,775.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6011158	A	20000104	US 1996-659983	19960607
	US 5656645	A	19970812	US 1995-484506	19950607
	US 5658930	A	19970819	US 1995-481660	19950607
	US 6008351	A	19991228	US 1995-573775	19951218
	WO 9746207	A2	19971211	WO 1997-US9818	19970609
	WO 9746207	A3	19980423		
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	AU 9733790	A1	19980105	AU 1997-33790	19970609
	US 6342504	B1	20020129	US 1999-194855	19991221
PRAI	US 1994-356833	A2	19941213		
	US 1995-481660	A2	19950607		
	US 1995-484506	A2	19950607		
	US 1995-573775	A2	19951218		
	WO 1995-US16410	A2	19951213		
	US 1996-659983	A	19960607		
	WO 1997-US9818	W	19970609		
OS	MARPAT 132:64536				
IT	199873-32-0P 199873-70-6P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of arom. heterocyclic derivs. as enzyme inhibitors)				
RN	199873-32-0 CAPLUS				

V. Balasubramanian

CN 1(2H)-Pyridineacetamide, N-[(2S,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199873-70-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2R,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 193278-20-5P 195204-07-0P 199873-27-3P
252860-83-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. heterocyclic derivs. as enzyme inhibitors)

RN 193278-20-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195204-07-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

V. Balasubramanian


CRN 195204-06-9
CMF C22 H30 N6 O5 S

Absolute stereochemistry.




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 199873-27-3 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252860-83-6 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 199873-29-5
CMF C22 H29 F N6 O5 S


Absolute stereochemistry.

V. Balasubramanian



CM 2

CRN 64-19-7
CMF C2 H4 O2



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1999:818256 CAPLUS
DN 132:50256
TI Preparation of aromatic heterocyclic derivatives as enzyme inhibitors
IN Tamura, Susan Yoshiko; Semple, Joseph Edward; Ripka, William Charles;
Ardecky, Robert John; Ge, Yu; Carpenter, Stephen H.; Brunck, Terence K.;
Lim-Wilby, Marguerita S. L.; Nutt, Ruth F.; Abelman, Matthew M.
PA Corvas International, Inc., USA
SO U.S., 80 pp., Cont.-in-part of U.S. 5,658,930.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6008351	A	19991228	US 1995-573775	19951218
	US 5656645	A	19970812	US 1995-484506	19950607
	US 5658930	A	19970819	US 1995-481660	19950607
	US 6011158	A	20000104	US 1996-659983	19960607
	US 6342504	B1	20020129	US 1999-194855	19991221
PRAI	US 1994-356833	A2	19941213		
	US 1995-481660	A2	19950607		
	US 1995-484506	A2	19950607		
	WO 1995-US16410	A2	19951213		
	US 1995-573775	A2	19951218		
	US 1996-659983	A2	19960607		
	WO 1997-US9818	W	19970609		

OS MARPAT 132:50256

IT 199873-32-0P 199873-70-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. heterocyclic derivs. as enzyme inhibitors)

V. Balasubramanian

RN 199873-32-0 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2S,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199873-70-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2R,3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 193278-20-5P 195204-07-0P 199873-27-3P
252860-83-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of arom. heterocyclic derivs. as enzyme inhibitors)

RN 193278-20-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195204-07-0 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)


V. Balasubramanian

CM 1

CRN 195204-06-9

CMF C22 H30 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 199873-27-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252860-83-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 199873-29-5

CMF C22 H29 F N6 O5 S

Absolute stereochemistry.



09/905,644

V. Balasubramanian



CM 2

CRN 64-19-7
CMF C2 H4 O2




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1999:275295 CAPLUS
DN 131:19283
TI Investigation of the S3 site of thrombin: design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating P1-argininals
AU Reiner, John E.; Lim-Wilby, Margeurita S.; Brunck, Terence K.; Ha-Uong, Theresa; Goldman, Erick A.; Abelman, Matthew A.; Nutt, Ruth F.; Semple, J. Edward; Tamura, Susan Y.
CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego, CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(6), 895-900
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
IT **226710-96-9**, CVS 1801
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis and biol. activity of pyridone-contg. peptidomimetic thrombin inhibitors, designed after thrombin S3 site)
RN 226710-96-9 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-2-oxo-3-[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



IT 226569-93-3P 226569-95-5P 226569-97-7P
226569-99-9P 226570-01-0P 226570-03-2P
226570-05-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and biol. activity of pyridone-contg. peptidomimetic thrombin inhibitors, designed after thrombin S3 site)

RN 226569-93-3 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[(methylsulfonyl)amino]-2-oxo-4-(2-phenylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226569-92-2

CMF C22 H30 N6 O5 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

V. Balasubramanian



RN 226569-95-5 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-4-(2-cyclohexylethyl)-3-[(methylsulfonyl)amino]-2-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226569-94-4

CMF C22 H36 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226569-97-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[(methylsulfonyl)amino]-2-oxo-4-(3-phenylpropyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 226569-96-6

CMF C23 H32 N6 O5 S

V. Balasubramanian


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226569-99-9 CAPLUS


CN 1(2H)-Pyridineacetamide, 3-(acetamino)-N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-2-oxo-4-(2-phenylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226569-98-8

CMF C23 H30 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

V. Balasubramanian



RN 226570-01-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-2-oxo-4-(2-phenylethyl)-3-[(phenylsulfonyl)amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226570-00-9

CMF C27 H32 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226570-03-2 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[[(methylamino) sulfonyl] amino]-2-oxo-4-(2-phenylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 226570-02-1

CMF C22 H31 N7 O5 S

09/905,644

V. Balasubramanian


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226570-05-4 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]-3-[(ethylsulfonyl)amino]-2-oxo-4-(2-phenylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226570-04-3

CMF C23 H32 N6 O5 S

Absolute stereochemistry.




09/905,644

V. Balasubramanian

CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 226570-11-2P 226570-13-4P 226570-15-6P
226570-17-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(synthesis and biol. activity of pyridone-contg. peptidomimetic
thrombin inhibitors, designed after thrombin S3 site)

RN 226570-11-2 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-ethoxy-3-
piperidinyl]-3-[(methylsulfonyl)amino]-2-oxo-4-(2-phenylethyl)-,
monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 226570-10-1

CMF C24 H34 N6 O5 S

Absolute stereochemistry.




CM 2

CRN 64-19-7

CMF C2 H4 O2

V. Balasubramanian



RN 226570-13-4 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-4-(2-cyclohexylethyl)-3-[(methylsulfonyl)amino]-2-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 226570-12-3

CMF C24 H40 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 226570-15-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-3-[(methylsulfonyl)amino]-2-oxo-4-(3-phenylpropyl)-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 226570-14-5

CMF C25 H36 N6 O5 S


Absolute stereochemistry.

V. Balasubramanian



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 226570-17-8 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-(acetylaminomethyl)-N-[(3S)-1-(aminoiminomethyl)-2-ethoxy-3-piperidiny]-4-(2-hydroxy-2-phenylethyl)-2-oxo-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 226570-16-7
CMF C25 H34 N6 O5

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1998:788773 CAPLUS
DN 130:66805
TI Preparation of peptide inhibitors of interleukin-1.beta. converting enzyme
IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.
PA Vertex Pharmaceuticals, Incorporated, USA
SO U.S., 106 pp., Cont.-in-part of U.S. 5,656,627.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5847135	A	19981208	US 1995-440898	19950525
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5656627	A	19970812	US 1995-405581	19950317
	US 5716929	A	19980210	US 1995-464964	19950605
	US 6103711	A	20000815	US 1995-465216	19950605
	CA 2192089	AA	19951228	CA 1995-2192089	19950616
	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9529446	A1	19960115	AU 1995-29446	19950616
AU 709114	B2	19990819			
EP 784628	A1	19970723	EP 1995-925257	19950616	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
CN 1159196	A	19970910	CN 1995-194381	19950616	
BR 9508051	A	19971021	BR 1995-8051	19950616	
HU 76622	A2	19971028	HU 1996-3475	19950616	
JP 10504285	T2	19980428	JP 1996-502478	19950616	
NO 9605365	A	19970217	NO 1996-5365	19961213	
FI 9605036	A	19970214	FI 1996-5036	19961216	
US 5973111	A	19991026	US 1997-828941	19970328	
PRAI	US 1994-261452	A2	19940617		
	US 1995-405581	A2	19950317		
	US 1995-440898	A3	19950525		
	WO 1995-US7617	W	19950616		
OS	MARPAT 130:66805				
IT	195071-90-0P 195071-91-1P 195071-92-2P 195071-93-3P 195071-94-4P 195071-95-5P 195071-97-7P 195071-98-8P 195071-99-9P 195072-00-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				

— — — — —

```

      (prepn. of peptide inhibitors of interleukin-1.beta. converting enzyme)

```

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

O=C1C(=O)N(C1Cc2ccccc2)C(=O)NCC(=O)N[C@@H]3C(=O)OC(C3)OCC4=CC=CC=C4


CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(2-phenylethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI)
(CA INDEX NAME)

O=C(NCCC1=CC=CC=C1)c2cc(NC(=O)CC3=C(C=C2)C(=O)N(C3)CC4=CC=CC=C4)ccc2C(=O)N[C@@H]5C(=O)OCC6=CC=CC=C6C5=O

CN 1(2H)-Pyridineacetamide, 6-butyl-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-
[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX
NAME)

09/905,644


V. Balasubramanian



RN 195071-93-3 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-methyl-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195071-94-4 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-phenyl-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195071-95-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195071-97-7 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[(2S)-2-(acetamino)-3-(4-hydroxyphenyl)-1-oxopropyl]amino]-2-oxo-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195071-98-8 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[[(2-phenylethyl)sulfonyl]amino]-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195071-99-9 CAPLUS

CN Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]amino]ethyl]-6-(phenylmethyl)-3-pyridinyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


•



RN 195072-00-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-4-phenylbutyl)amino]-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1998:1379 CAPLUS

DN 128:48502

TI Preparation of aromatic heterocyclic peptide aldehydes as enzyme inhibitors

IN Tamura, Susan Yoshiko; Semple, Joseph Edward; Ardecky, Robert John; Ge,
Yu; Ripka, William Charles; Brunck, Terence Kevin; Lim-Wilby, Marguerita
S.

PA Corvas International, Inc., USA; Tamura, Susan Yoshiko; Semple, Joseph Edward; Ardecky, Robert John; Ge, Yu; Ripka, William Charles; Brunck, Terence Kevin; Lim-Wilby, Marguerita S.

SO PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 7

PATENT NO.


KIND	DATE
------	------

APPLICATION NO. DATE

09/905,644

PI	WO 9746207	A2	19971211	WO 1997-US9818	19970609
	WO 9746207	A3	19980423		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6011158	A	20000104	US 1996-659983	19960607
	AU 9733790	A1	19980105	AU 1997-33790	19970609
	US 6342504	B1	20020129	US 1999-194855	19991221
PRAI	US 1996-659983	A	19960607		
	US 1994-356833	A2	19941213		
	US 1995-481660	A2	19950607		
	US 1995-484506	A2	19950607		
	WO 1995-US16410	A2	19951213		
	US 1995-573775	A2	19951218		
	WO 1997-US9818	W	19970609		
OS	MARPAT 128:48502				
IT	193278-20-5P 193278-22-7P 195204-07-0P 195204-23-0P 195204-25-2P 195204-28-5P 195315-31-2P 199873-27-3P 199873-29-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(prepn. of arom. heterocyclic peptide aldehydes as enzyme inhibitors)				
RN	193278-20-5 CAPLUS				
CN	1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 193278-22-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-6-methyl-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 195204-07-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-oxo-3-[[phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 195204-06-9

CMF C22 H30 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 195204-23-0 CAPLUS

CN Carbamic acid, [1-[2-[[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/905,644

V. Balasubramanian



RN 195204-25-2 CAPLUS


CN Carbamic acid, [1-[2-[[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 195204-24-1

CMF C21 H34 N6 O5


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 195204-28-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[[5-chloro-2-methoxyphenyl]sulfonyl]amino]-N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/905,644

V. Balasubramanian

RN 195315-31-2 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-6-methyl-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 195315-30-1

CMF C23 H32 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 199873-27-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/905, 644

V. Balasubramanian

RN 199873-29-5 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-3-
[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo-, (3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




IT 199873-32-0P 199873-70-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. heterocyclic peptide aldehydes as enzyme inhibitors)

RN 199873-32-0 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2S,3S)-1-(aminoiminomethyl)-2-hydroxy-3-
piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 199873-70-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[(2R,3S)-1-(aminoiminomethyl)-2-hydroxy-3-
piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1997:574513 CAPLUS

DN 127:234607

TI Preparation of aromatic heterocyclic arginine aldehyde derivatives as
thrombin inhibitors

IN Tamura, Susan Yoshiko; Semple, Joseph Edward; Ripka, William Charles;


V. Balasubramanian

Ardecky, Robert John; Ge, Yu; Carpenter, Stephen H.; Brunck, Terence K.
PA Corvas International, Inc., USA
SO U.S., 68 pp. Cont.-in-part of U.S. Ser. No. 356,833.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5658930	A	19970819	US 1995-481660	19950607
CA 2206400	AA	19960620	CA 1995-2206400	19951213
WO 9618644	A1	19960620	WO 1995-US16410	19951213
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9644248	A1	19960703	AU 1996-44248	19951213
AU 693636	B2	19980702		
EP 804464	A1	19971105	EP 1995-943130	19951213
EP 804464	B1	20020508		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
BR 9509994	A	19971230	BR 1995-9994	19951213
CN 1169730	A	19980107	CN 1995-196753	19951213
JP 10510539	T2	19981013	JP 1995-519290	19951213
US 6008351	A	19991228	US 1995-573775	19951218
US 6011158	A	20000104	US 1996-659983	19960607
HU 77888	A2	19951213	HU 1998-1160	19980928
US 6342504	B1	20020129	US 1999-194855	19991221
PRAI US 1994-356833	A2	19941213		
US 1995-481660	A	19950607		
US 1995-484506	A	19950607		
WO 1995-US16410	W	19951213		
US 1995-573775	A2	19951218		
US 1996-659983	A2	19960607		
WO 1997-US9818	W	19970609		
OS MARPAT 127:234607				
IT 193278-20-5P 193278-22-7P 195204-07-0P				
195204-23-0P 195204-25-2P 195204-28-5P				
195315-31-2P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of arom. heterocyclic arginine aldehyde derivs. as thrombin inhibitors)				
RN 193278-20-5	CAPLUS			
CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidiny]-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


V. Balasubramanian



RN 193278-22-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-6-methyl-2-oxo-3-[(phenylmethyl)sulfonyl]amino-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195204-07-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-oxo-3-[(phenylmethyl)sulfonyl]amino-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 195204-06-9

CMF C22 H30 N6 O5 S


Absolute stereochemistry.



CM 2


V. Balasubramanian

CRN 64-19-7
CMF C2 H4 O2



RN 195204-23-0 CAPLUS
CN Carbamic acid, [1-[2-[[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195204-25-2 CAPLUS
CN Carbamic acid, [1-[2-[[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 195204-24-1
CMF C21 H34 N6 O5

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2




V. Balasubramanian

RN 195204-28-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[[5-chloro-2-methoxyphenyl)sulfonyl]amino]-N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidiny]-2-oxo-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 195315-31-2 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidiny]-6-methyl-2-oxo-3-[[[phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 195315-30-1

CMF C23 H32 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2




V. Balasubramanian

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1997:541856 CAPLUS
DN 127:234613
TI Aromatic heterocyclic derivatives as enzyme inhibitors
IN Tamura, Susan Yoshiko; Semple, Joseph Edward; Ripka, William Charles;
Ardecky, Robert John; Ge, Yu; Carpenter, Stephen H.; Brunck, Terence K.
PA Corvas International, Inc., USA
SO U.S., 65 pp., ont.-in-part of U.S. Ser. No. 356,833.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5656645	A	19970812	US 1995-484506	19950607
	CA 2206400	AA	19960620	CA 1995-2206400	19951213
	WO 9618644	A1	19960620	WO 1995-US16410	19951213
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9644248	A1	19960703	AU 1996-44248	19951213
	AU 693636	B2	19980702		
	EP 804464	A1	19971105	EP 1995-943130	19951213
	EP 804464	B1	20020508		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
	BR 9509994	A	19971230	BR 1995-9994	19951213
	CN 1169730	A	19980107	CN 1995-196753	19951213
	JP 10510539	T2	19981013	JP 1995-519290	19951213
	US 6008351	A	19991228	US 1995-573775	19951218
	US 6011158	A	20000104	US 1996-659983	19960607
	HU 77888	A2	19951213	HU 1998-1160	19980928
	US 6342504	B1	20020129	US 1999-194855	19991221
PRAI	US 1994-356833	A2	19941213		
	US 1995-481660	A	19950607		
	US 1995-484506	A	19950607		
	WO 1995-US16410	W	19951213		
	US 1995-573775	A2	19951218		
	US 1996-659983	A2	19960607		
	WO 1997-US9818	W	19970609		
OS	MARPAT 127:234613				
IT	193278-20-5P 195204-07-0P 195204-23-0P 195204-25-2P 195204-28-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of arom. peptide aldehydes as thrombin inhibitors)				
RN	193278-20-5 CAPLUS				
CN	1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

V. Balasubramanian



RN 195204-07-0 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-oxo-3-[[phenylmethyl)sulfonyl]amino]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 195204-06-9

CMF C22 H30 N6 O5 S


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 195204-23-0 CAPLUS

CN Carbamic acid, [1-[2-[[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/905,644

V. Balasubramanian

RN 195204-25-2 CAPLUS


CN Carbamic acid, [1-[2-[[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 195204-24-1

CMF C21 H34 N6 O5


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 195204-28-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[[5-chloro-2-methoxyphenyl)sulfonyl]amino]-N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1997:541852 CAPLUS

DN 127:234612

TI Preparation of heterocyclyl aspartaldehyde peptide derivatives as interleukin-1.β. converting enzyme inhibitors

IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael

V. Balasubramanian

D.; Murcko, Mark A.; Livingston, David J.

PA Vertex Pharmaceuticals, Inc., USA

SO U.S., 67 pp. Cont.-in-part of U.S. Ser. No. 261,452.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5656627	A	19970812	US 1995-405581	19950317
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5847135	A	19981208	US 1995-440898	19950525
	US 5716929	A	19980210	US 1995-464964	19950605
	US 6025147	A	20000215	US 1995-460973	19950605
	ZA 9504988	A	19961217	ZA 1995-4988	19950615
	CA 2192089	AA	19951228	CA 1995-2192089	19950616
	WO 9535308	A1	19951228	WO 1995-US7617	19950616

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT

RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9529446 A1 19960115 AU 1995-29446 19950616

AU 709114 B2 19990819

EP 784628 A1 19970723 EP 1995-925257 19950616

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

CN 1159196 A 19970910 CN 1995-194381 19950616

BR 9508051 A 19971021 BR 1995-8051 19950616

HU 76622 A2 19971028 HU 1996-3475 19950616

JP 10504285 T2 19980428 JP 1996-502478 19950616

NO 9605365 A 19970217 NO 1996-5365 19961213

FI 9605036 A 19970214 FI 1996-5036 19961216

US 5973111 A 19991026 US 1997-828941 19970328

PRAI US 1994-261452 A2 19940617

US 1995-405581 A2 19950317

US 1995-440898 A3 19950525

WO 1995-US7617 W 19950616

OS MARPAT 127:234612

IT 195071-90-0P 195071-91-1P 195071-92-2P

195071-93-3P 195071-94-4P 195071-95-5P

195071-97-7P 195071-98-8P 195071-99-9P

195072-00-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of heterocyclyl aspartaldehyde peptide derivs. as
interleukin-1.beta. converting enzyme inhibitors)

RN 195071-90-0 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195071-91-1 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(2-phenylethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 195071-92-2 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-butyl-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195071-93-3 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-methyl-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195071-94-4 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-phenyl-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195071-95-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195071-97-7 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[(2S)-2-(acetamino)-3-(4-hydroxyphenyl)-1-oxopropyl]amino]-2-oxo-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195071-98-8 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[[(2-phenylethyl)sulfonyl]amino]-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195071-99-9 CAPLUS

CN Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]amino]ethyl]-6-(phenylmethyl)-3-pyridinyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 195072-00-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-4-phenylbutyl)amino]-6-(phenylmethyl)-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1997:423751 CAPLUS

DN 127:149377

TI Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates

AU Tamura, Susan Y.; Semple, J. Edward; Reiner, John E.; Goldman, Erick A.; Brunck, Terence K.; Lim-Wilby, Marguerita S.; Carpenter, Stephen H.; Rote, William E.; Oldeshulte, Gerard L.; Richard, Brigitte M.; Nutt, Ruth F.; Ripka, William C.

CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego, CA, 92121, USA

SO Bioorg. Med. Chem. Lett. (1997), 7(12), 1543-1548

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier

DT Journal

LA English

IT 193278-10-3P 193278-11-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


V. Balasubramanian

(design and synthesis of thrombin inhibitors incorporating heterocyclic dipeptide surrogates)

RN 193278-10-3 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-hydroxy-3-piperidiny]-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 193278-11-4 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-hydroxy-3-piperidiny]-6-methyl-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 193278-20-5P 193278-22-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)


(design and synthesis of thrombin inhibitors incorporating heterocyclic dipeptide surrogates)

RN 193278-20-5 CAPLUS

V. Balasubramanian

CN 1(2H)-Pyridineacetamide, N-[(3S)-2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193278-22-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-6-methyl-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1996:479294 CAPLUS

DN 125:143331

TI Preparation of aromatic heterocyclic peptide aldehydes as thrombin inhibitors

IN Tamura, Susan Yoshiko; Semple, Joseph Edward; Ripka, William Charles; Ardecky, Robert John; Ge, Yu; Carpenter, Stephen H.; Brunck, Terence Kevin; Lim-Wilby, Marguerita S.; Nutt, Ruth F.; Abelman, Matthew Mark

PA Corvas International, Inc., USA

SO PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9618644	A1	19960620	WO 1995-US16410	19951213
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,				

09/905,644

V. Balasubramanian

GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
 MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
 TM, TT
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
 IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
 NE, SN, TD, TG

US 5656645	A	19970812	US 1995-484506	19950607
US 5658930	A	19970819	US 1995-481660	19950607
AU 9644248	A1	19960703	AU 1996-44248	19951213
AU 693636	B2	19980702		
EP 804464	A1	19971105	EP 1995-943130	19951213
EP 804464	B1	20020508		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV

BR 9509994	A	19971230	BR 1995-9994	19951213
JP 10510539	T2	19981013	JP 1995-519290	19951213
US 6342504	B1	20020129	US 1999-194855	19991221

PRAI US 1994-356833 A 19941213
 US 1995-481660 A 19950607
 US 1995-484506 A 19950607
 WO 1995-US16410 W 19951213
 US 1995-573775 A2 19951218
 US 1996-659983 A2 19960607
 WO 1997-US9818 W 19970609


OS CASREACT 125:143331; MARPAT 125:143331

IT **179523-54-7P 179523-56-9P 179523-61-6P**
179523-63-8P 179524-26-6P 179524-28-8P
179524-52-8P 179524-65-3P 179524-66-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of arom. heterocyclic peptide aldehydes as thrombin inhibitors)

RN 179523-54-7 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-
 piperidinyl]-2-oxo-3-[(phenylmethyl)sulfonyl]amino]- (9CI) (CA INDEX
 NAME)



RN 179523-56-9 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-2-
 oxo-3-[(phenylmethyl)sulfonyl]amino]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 179523-55-8

CMF C22 H30 N6 O5 S


V. Balasubramanian



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 179523-61-6 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[2-ethoxy-1-[[imino(nitroamino)methyl]-3-piperidinyl]-6-methyl-2-oxo-3-[[phenylmethylsulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 179523-63-8 CAPLUS


CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-6-methyl-2-oxo-3-[[phenylmethylsulfonyl]amino]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 179523-62-7


CMF C23 H32 N6 O5 S

V. Balasubramanian




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 179524-26-6 CAPLUS

CN Carbamic acid, [1-[2-[[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 179524-28-8 CAPLUS

CN Carbamic acid, [1-[2-[[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]methyl-, 1,1-dimethylethyl ester, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 179524-27-7
CMF C21 H34 N6 O5




09/905,644


V. Balasubramanian

CM 2


CRN 64-19-7
CMF C2 H4 O2




RN 179524-52-8 CAPLUS
CN 1(2H)-Pyridineacetamide, 3-[[(5-chloro-2-methoxyphenyl) sulfonyl] amino]-N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 179524-65-3 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[2-ethoxy-1-[imino(nitroamino)methyl]-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 179524-66-4 CAPLUS
CN 1(2H)-Pyridineacetamide, N-[1-(aminoiminomethyl)-2-ethoxy-3-piperidinyl]-3-[[[(2-fluorophenyl)methyl]sulfonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1996:214750 CAPLUS

09/905,644

V. Balasubramanian

DN 124:290273
TI Preparation of peptide analogs as inhibitors of interleukin-1 beta
converting enzyme (ICE)
IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael
D.; Murcko, Mark A.; Livingston, David J.
PA Vertex Pharmaceuticals Incorp., USA
SO PCT Int. Appl., 374 pp.
CODEN: PIXXD2


DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5656627	A	19970812	US 1995-405581	19950317
	US 5847135	A	19981208	US 1995-440898	19950525
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	BR 9508051	A	19971021	BR 1995-8051	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
PRAI	US 1994-261452	A	19940617		
	US 1995-405581	A	19950317		
	US 1995-440898	A	19950525		
	WO 1995-US7617	W	19950616		
OS	MARPAT 124:290273				
IT	175210-95-4P 175210-96-5P 175210-97-6P 175210-98-7P 175210-99-8P 175211-00-4P 175211-02-6P 175211-03-7P 175211-04-8P 175211-05-9P 175415-27-7P 175415-28-8P 175415-29-9P 175415-30-2P 175415-31-3P 175415-32-4P 175415-33-5P 175415-34-6P 175415-35-7P 175415-36-8P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)				
RN	175210-95-4 CAPLUS				
CN	1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


V. Balasubramanian



RN 175210-96-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(2-phenylethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175210-97-6 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-(1,1-dimethylethyl)-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175210-98-7 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-methyl-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175210-99-8 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-phenyl-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175211-00-4 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175211-02-6 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[2-(acetylamino)-1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]amino]-2-oxo-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, [2R-[2.alpha.,3.alpha.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175211-03-7 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[[2-(phenylethyl)sulfonyl]amino]-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175211-04-8 CAPLUS

CN Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]amino]ethyl]-6-(phenylmethyl)-3-pyridinyl]-, 2-phenylethyl ester, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175211-05-9 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-4-phenylbutyl)amino]-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175415-27-7 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175415-28-8 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(2-phenylethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175415-29-9 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-(1,1-dimethylethyl)-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175415-30-2 CAPLUS

CN 1(2H)-Pyridineacetamide, 6-methyl-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175415-31-3 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-phenyl-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175415-32-4 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175415-33-5 CAPLUS

CN 1(2H)-Pyridineacetamide, 3-[[2-(acetamino)-1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]amino]-2-oxo-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, [2S-[2.alpha.,3.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175415-34-6 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[[(2-phenylethyl) sulfonyl] amino]-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175415-35-7 CAPLUS

CN Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl] amino]ethyl]-6-(phenylmethyl)-3-pyridinyl]-, 2-phenylethyl ester, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 175415-36-8 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-3-[(1-oxo-4-phenylbutyl)amino]-6-(phenylmethyl)-N-[tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]-, (2S-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

43.17

184.04

STN INTERNATIONAL LOGOFF AT 13:13:26 ON 27 MAY 2002